R. Lafferty

发表

Galleria mellonella as a novel in vivo model for assessment of the toxicity of 1-alkyl-3-methylimidazolium chloride ionic liquids.

J. Megaw, Thomas P Thompson, R. Lafferty, 2015, Chemosphere.

Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity.

N. Irwin, P. Flatt, R. Lafferty, 2020, Metabolism: clinical and experimental.

Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes induction.

N. Irwin, P. Flatt, R. Lafferty, 2020, Biochimica et biophysica acta. General subjects.

Peptide YY (1–36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β‐cell function, growth and survival

Yang De Marinis, N. Irwin, P. Flatt, 2020, Diabetes, obesity & metabolism.

PYY(1-36) peptides from phylogenetically ancient fish targeting mammalian NPY1 receptors demonstrate potent effects on pancreatic beta-cell function, growth and survival

N. Irwin, P. Flatt, R. Lafferty, 2019 .

Is polypharmacy the future for pharmacological management of obesity?

N. Irwin, P. Flatt, R. Lafferty, 2022, Current Opinion in Endocrine and Metabolic Research.

Ac3IV, a V1a and V1b receptor selective vasopressin analogue, protects against hydrocortisone-induced changes in pancreatic islet cell lineage

N. Irwin, P. Flatt, R. Lafferty, 2022, Peptides.

Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes.

N. Irwin, P. Flatt, R. Lafferty, 2020, Current opinion in endocrinology, diabetes, and obesity.

Effects of 2 Novel PYY(1-36) Analogues, (P3L31P34)PYY(1-36) and PYY(1-36)(Lys12PAL), on Pancreatic Beta-Cell Function, Growth, and Survival

N. Irwin, P. Flatt, R. Lafferty, 2019, Clinical medicine insights. Endocrinology and diabetes.

Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice.

N. Irwin, P. Flatt, R. Lafferty, 2022, Biochimie.

Beneficial impact of Ac3IV, an AVP analogue acting specifically at V1a and V1b receptors, on diabetes islet morphology and transdifferentiation of alpha- and beta-cells

N. Irwin, P. Flatt, R. Lafferty, 2021, PloS one.

Macroalgal protein hydrolysates from Palmaria palmata influence the ‘incretin effect’ in vitro via DPP-4 inhibition and upregulation of insulin, GLP-1 and GIP secretion

R. Fitzgerald, E. McSorley, R. Lafferty, 2021, European Journal of Nutrition.

Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice

N. Irwin, P. Flatt, R. Lafferty, 2022, The Journal of endocrinology.

Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists

N. Irwin, P. Flatt, R. Lafferty, 2022, Diabetes, obesity & metabolism.

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes

Andrew English, N. Irwin, P. Flatt, 2021, Frontiers in Endocrinology.

Effects of artemether on pancreatic islet morphology, islet cell turnover and α-cell transdifferentiation in insulin-deficient GluCreERT2;ROSA26-eYFP diabetic mice.

N. Irwin, P. Flatt, A. Tarasov, 2022, The Journal of pharmacy and pharmacology.

Physicochemical, Nutritional and In Vitro Antidiabetic Characterisation of Blue Whiting (Micromesistius poutassou) Protein Hydrolysates

J. Whooley, S. Gite, R. Fitzgerald, 2021, Marine drugs.

Proglucagon-Derived Peptides as Therapeutics

N. Irwin, P. Flatt, R. Lafferty, 2021, Frontiers in Endocrinology.

Pharmacology of Gut Hormone Mimetics for Obesity and Diabetes

N. Irwin, P. Flatt, R. Lafferty, 2021 .

Antidiabetic actions of GPR55 agonist Abn-CBD and sitagliptin in obese-diabetic high fat fed mice.

P. Flatt, R. Lafferty, A. McCloskey, 2022, Biochemical pharmacology.

Emerging therapeutic potential for peptide YY for obesity-diabetes

N. Irwin, P. Flatt, R. Lafferty, 2018, Peptides.

GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy

N. Irwin, P. Flatt, R. Lafferty, 2023, Expert opinion on pharmacotherapy.

Protein hydrolysates from boarfish (Capros aper) and Atlantic salmon (Salmo salar) skin gelatin improve metabolic control in genetically obese diabetic (ob/ob) mice

R. Fitzgerald, E. McSorley, R. Lafferty, 2021, Journal of Food Bioactives.

Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice

F. Reimann, F. Gribble, N. Irwin, 2021, Frontiers in Endocrinology.

The glucagon receptor antagonist desHis1Pro4Glu9-glucagon(Lys12PAL) alters alpha-cell turnover and lineage in mice, but does not cause alpha-cell hyperplasia

N. Irwin, P. Flatt, R. Lafferty, 2023, Molecular and Cellular Endocrinology.

Solving Complex Dual-Water Equation using Dielectric-NMR-Spectroscopy and Conventional Logs

R. Lafferty, W. Tan, T. Neville, 2014 .

C‐terminal degradation of PYY peptides in plasma abolishes effects on satiety and beta‐cell function

N. Irwin, R. Lafferty, P. Flatt, 2018, Biochemical pharmacology.

NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?

N. Irwin, R. Lafferty, Peter R. Flatt, 2024, Peptides.